Intrauterine Fetal Demise After Uncomplicated COVID-19: What Can We Learn from the Case?

Background: SARS-CoV-2 infection in pregnant women can lead to placental damage and transplacental infection transfer, and intrauterine fetal demise is an unpredictable event. Case study: A 32-year-old patient in her 38th week of pregnancy reported loss of fetal movements. She overcame mild COVID-19 with positive PCR test 22 days before. A histology of the placenta showed deposition of intervillous fibrinoid, lympho-histiocytic infiltration, scant neutrophils, clumping of villi, and extant infarctions. Immunohistochemistry identified focal SARS-CoV-2 nucleocapsid and spike protein in the syncytiotrophoblast and isolated in situ hybridization of the virus’ RNA. Low ACE2 and TMPRSS2 contrasted with strong basigin/CD147 and PDL-1 positivity in the trophoblast. An autopsy of the fetus showed no morphological abnormalities except for lung interstitial infiltrate, with prevalent CD8-positive T-lymphocytes and B-lymphocytes. Immunohistochemistry and in situ hybridization proved the presence of countless dispersed SARS-CoV-2-infected epithelial and endothelial cells in the lung tissue. The potential virus-receptor protein ACE2, TMPRSS2, and CD147 expression was too low to be detected. Conclusion: Over three weeks’ persistence of trophoblast viral infection lead to extensive intervillous fibrinoid depositions and placental infarctions. High CD147 expression might serve as the dominant receptor for the virus, and PDL-1 could limit maternal immunity in placental tissue virus clearance. The presented case indicates that the SARS-CoV-2 infection-induced changes in the placenta lead to ischemia and consecutive demise of the fetus. The infection of the fetus was without significant impact on its death. This rare complication of pregnancy can appear independently to the severity of COVID-19’s clinical course in the pregnant mother.

562. Tocilizumab Use in the Second Trimester Pregnant Patients with Severe Covid-19 Pneumonia and their Maternal and Fetal Outcomes: Two Case Reports

Background Tocilizumab is an interleukin-6 monoclonal antibody with widespread use in rheumatologic conditions. Observational studies have shown a promising role of Tocilizumab in severe COVID-19 patients with cytokine storm syndrome. Data about tocilizumab use in pregnant patients is limited. We report two outcomes of two pregnant patients with COVID-19 in the second trimester who received tocilizumab Methods A 24-year-old 20 weeks pregnant lady with a history of asthma and gestational diabetes mellitus presented with three days history of fever, cough and shortness of breath (Figure 1). She was clinically stable but later developed ARDS and developed increased oxygen demand up to 10 liters/min. She received Tocilizumab on. Patient was observed in a high dependency unit but did not require mechanical ventilation. Patient was discharged home with full recovery and later delivered a healthy baby. Timeline of medicines used during hospital (Figure 2). Case 2: 39-year-old 23 weeks pregnant lady presented with seven days history of fever cough and shortness of breath (Figure 1). On presentation, she had progressive worsening hypoxic respiratory failure and was intubated. Patient had her nasopharyngeal swab for CODI-19 RT PCR was positive. The patient had severe ARDS requiring ECMO (extracorporeal membrane oxygenation) for respiratory support. Tocilizumab 400 mg was given on the presentation, along with other medications (Figure 3). Patient had regular monitoring of fetus; however, she had intrauterine fetal demise on day 14. Patient It is unclear if IUFD was due to using of tocilizumab or severity of COVID19 itself. The patient stayed in ICU for 20 days and was discharged after full recovery. Figure 1. Case 1 treatment timeline. Abberviations: Azithro: Azithromycin, HCQ: Hydroxychloroquine, CQ: Chloroquine, LPV/r: lopinavir/Ritonavir, Osel: Oseltamivir, MP: Methylprednisolone, Ampi-sulb: Ampicillin-sulbactam, TCZ: tocilizumab Figure 2. Case 2 treatment timeline Results Learning points: Tocilizumab use in pregnant patients with severe COVID-19 pneumonia during the second trimester improved maternal outcomes in our cases. Tocilizumab use may be associated with worse fetal outcomes, including intrauterine fetal demise (IUFD). Figure 3. Table of clinical characteristics, pregnant outcomes. Abbreviations: LRTI: lower respiratory tract infection, HCQ: Hydroxychloroquine, CQ: chloroquine, Osel: Oseltamivir, Cef: Ceftrixone, Ampi-Sulb: ampicillin-sulbactam, Azithro: Azithromycin, TCZ: tocilizumab, MP: methylpredinisolone, H/O: History of, LSCS: C-section, NA: not available. Pip-tazo: Piperacillin-tazobactam, Mero: Meropenem, Sulfa-trim: Sulfamethoxazole-Trimethoprim, IUFD: Intrauterine fetal death. Conclusion The pharmacological management of pregnant patients with severe COVID-19 pneumonia poses significant challenges. The use of Tocilizumab may improve maternal outcomes but may also increase the risk of worse fetal outcomes. Caution should be exercised in using this agent, and risks and benefits should be discussed with the patients. Disclosures All Authors: No reported disclosures

Echogenic Intestine: a Case of Intrauterine Fetal Demise at Term

Introduction/Objective Parvovirus B19 is a non-enveloped, single-stranded DNA virus that preferentially infects early erythroids, and is commonly associated with second trimester hydrops fetalis. Third trimester non-hydropic intrauterine fetal demise due to parvovirus B19 infection with associated pathologic changes has rarely been described, particularly in the context of IgG seroconverted mother. Methods/Case Report We present a case of a 37 weeks’ gestation stillborn female fetus born to a 29 year-old mother who presented with lack of fetal movement for one day. Fetal ultrasound demonstrated diffuse intestinal echogenicity. Maternal parvovirus B19 IgG level was high (5.48, reference: <=0.90 Index). Postmortem examination revealed a non-dysmorphic fetus. Gross examination was unremarkable. Microscopic examination of small intestine revealed mucosal inflammation and multifocal calcifications. Prominent extramedullary hematopoiesis was present in the liver. Viral cytopathic effect was noted microscopically within nucleated red blood cells present intravascularly within chorionic villi, small intestine, liver, and spleen. Parvovirus B19 infection was confirmed by immunohistochemistry. Results (if a Case Study enter NA) NA Conclusion The cause of clinically puzzling intrauterine fetal demise at term with prominent intestinal echogenicity on ultrasound was determined to be parvovirus B19 infection on postmortem examination. We emphasize the possibility of this diagnostic differential in non-hydropic, third trimester fetal demise in presence of maternal IgG seroconversion and lack of signs of active infection.

Maternal and Fetal Outcomes of COVID-19 Positive Pregnant Women in Government T.D. Medical College Alappuzha

BACKGROUND Corona virus disease 2019 (COVID 19) outbreak have evolved rapidly throughout the world. The knowledge on severe acute respiratory disease-corona virus-2 (SARS-CoV-2) infection in pregnant women and newborn is incomplete. Understanding the impact of COVID 19 in pregnancy in terms of morbidity mortality, perinatal and neonatal outcome is essential to propose a strategy for the management of pregnant women with COVID 19 infection. METHOD It is a prospective study of all pregnant women who have delivered in the period of April 2020 to December 2020 at Government T.D. Medical College, Alappuzha. In this study, the mode of delivery, neonatal outcome, maternal mortality, morbidity were evaluated. The outcome of pregnancies includes vaginal delivery, caesarean delivery, vacuum delivery and intrauterine fetal demise. RESULTS A total of 265 pregnant women infected with COVID 19 delivered during the period. Out of these, 49.4 % was full term caesarean delivery, 3.8 % was preterm caesarean delivery, 39.3 % was full term vaginal delivery and 4.9 % was preterm vaginal delivery. Moreover, 1.1 % of the total pregnant women had intrauterine fetal demise on admission. Among 265 new-borns, 2.3 % babies became COVID 19 positive, of this, 83.3 % were mothers who delivered within 7 days of COVID 19 infection. 0.75 % needed resuscitative emergency caesarean delivery for COVID 19 pneumonia. 0.38 % maternal mortality occurred during the period due to COVID 19 infection. CONCLUSIONS Obstetric outcome in most COVID 19 infected term pregnant patients is comparable to non-COVID 19 pregnant women except for a higher incidence of caesarean delivery. Most of the neonates who became positive were born to mothers delivered within 7 days of COVID 19 infection. Severe morbidity among COVID 19 pregnant women were seen only in a small proportion complicated by COVID 19 pneumonia, who required ventilator support. KEYWORDS COVID 19, Pregnancy, Maternal, Perinatal, Neonatal Outcome

THE IMPACT OF ISOLATED OLIGOHYDRAMNIAS AT TERM ON PERINATAL OUTCOME: A COMPARATIVE STUDY

Objective: To study the impact of isolated oligohydramnios at term on mode of delivery and perinatal outcome. Study Design: Prospective comparative study. Place and Duration of Study: Combined Military Hospital Okara, from Aug 2019 to Aug 2020. Methodology: A total of 250 patients were recruited in the study. They were divided in 2 groups. In group A there was 123 patients, with isolated oligohydramnias at term, amniotic fluid index of ≤5cm, while in group B 127 patients, with normal liquor volume were included through lottery method. Demographic parameters, Intrauterine fetal demise, mode of delivery, perinatal out comes like meconium stained amniotic fluid, low birth weight, APGAR score at 1 and 5 minutes, of two groups were compared. Results: A total of 57 (46.3%) patients in group A delivered through cesarean section and 27 (21.3%) in group B. Meconium staining of liquor was in 56 (45.5%) in group A versus 13 (10.2%) in group B. As compared to group B the patients in group A lower birth weight babies 2.6 ± 0.34 kg versus 3.0 ± 0.33 kg were delivered. Mortality in group A, intrauterine fetal demise was 4 (3.3%) and still birth was 2.3%. There were no perinatal mortality in controlled group B. Conclusion: Isolated oligohydramnias at term is not associated with adverse perinatal outcome. Umbilical cord compression, potential utero-placental insuffiency and increased incidence of meconium stained liquor possibly explains the increased perinatal morbidity. The delivery should be routinely advocated as in otherwise uncomplicated pregnancy with appropriately grown fetus.